IMR Press / CEOG / Volume 23 / Issue 4 / pii/1996046

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

EGF/EGF-R system and benign breast disease during and following the treatment of gynaecological pathologies with an analogue of LH-RH

Show Less
1 University of Naples “Federico II”, Medical School, Department of Gynaecology, Obstetncs and Physiopathology of Human Reproduction
2 Department of Pathology, University of Naples “Federico II”, Medical School
Clin. Exp. Obstet. Gynecol. 1996, 23(4), 220–228;
Published: 10 December 1996
Abstract

Clinical and pathological changes of the mammary gland have been studied in 64 women affected by symptomatic Benign Breast Disease (BBD) coexisting with endometriosis or uterine leiomyomata. These patients were rendered hypoestrogenic by subcutaneous administration of the LH-RH analogue Goserelin depot [D-ser (tBu)6 Aza-Gly10-GnRH (ICI118630)] performed every 28 days, for six months. They were evaluated clinically and ultrasonographically before and after treatment to find possible changes of BBD as well as of endometriosis or uterine leiomyomata. Mammary biopsies were performed before and after treatment in all the patients to study the changes of EGF-R expression. Results showed that clinical improvement is accompanied with a reduction of EGF-R expression.

Keywords
EGF /EGF-R system
Benign Breast Disease
LB-RH analogue
Share
Back to top